Navigation Links
Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Date:4/27/2009

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer

PARSIPPANY, N.J., April 27 /PRNewswire/ -- Ferring Pharmaceuticals announced today the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. The announcement was made at the 2009 American Urological Association Annual Meeting in Chicago, IL.

The Phase IIIB trial will investigate the use of degarelix for intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. The study will compare IADT to continuous androgen deprivation therapy (ADT) for 14 months with either leuprolide or degarelix. The trial evaluates whether IADT minimizes the negative effects of ADT and maximizes quality of life, while maintaining tumor response as measured by PSA suppression.

"Intermittent androgen deprivation therapy is a commonly employed treatment for men with biochemical failure, however it needs to be evaluated in a randomized clinical trial," says Dr. E. David Crawford, Head Urologic Oncology, University of Colorado, Denver and a trial investigator. "There is potential value in combining the rapid, sustained suppression of testosterone that degarelix offers in this treatment. IADT appears to improve patient quality of life and that will also be evaluated."

Physicians interested in serving as trial investigators should call 1-973-796-1600 to speak with Ferring Pharmaceuticals' Medical Information office.

Degarelix Phase III Trials

Phase III pivotal studies showed that degarelix is as effective as leuprolide (Lupron Depot(R))(*)in reducing and sustaining castrate levels
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Oct. 1 VirtualScopics, Inc. (Nasdaq: VSCP ), ... revenues for the third quarter ended September 30, 2010 exceeded ... comparable period in 2009 and a greater than 9% growth ... increased over 30% for the period ended September 30, 2010 ...
... 1 Palatin Technologies, Inc. (NYSE Amex: PTN ... Annual BIO Investor Forum on Wednesday, October 6, 2010 at ... the 9th Annual BIO Investor Forum will take place October ... Carl Spana, Ph.D., President and Chief Executive Officer ...
Cached Medicine Technology:VirtualScopics Revenues Hit Another Quarterly Record 2VirtualScopics Revenues Hit Another Quarterly Record 3
(Date:12/25/2014)... December 25, 2014 BambooFlooringChina.com sells many ... quality bamboo flooring. Today, the company announces big ... many styles and colors. , BambooFlooringChina.com is the world’s ... the promotion is valid until Jan. 20, 2015. , ... and woven with a natural thread. All the bamboo ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... (HealthDay News) -- Overeating is common during the holidays, but ... an expert says. "Don,t arrive at a party hungry. ... know you,ll be attending a party, but deprivation leads to ... at Northern Westchester Hospital in Mount Kisco, N.Y., said in ... during the day and even to have a snack before ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... National Institutes of Health grant will help University of ... the damage caused by multiple sclerosis and other neurological ... College of Medicine and a member of UCF,s Hybrid ... a four-year, $1.9 million project. His team will study ...
... individualized therapy and better supportive care helped push the ... 71 percent three years after diagnosis, according to new ... and reported in the medical journal The Lancet ... 20 percent better than previously reported U.S. rates and ...
... with dyslexia often struggle with reading, writing, and spelling, ... in other areas. New neurological research has found that ... to structural differences within an important information highway in ... language. The findings are published in the June 2010 ...
... ... Zvetco Biometrics today announced that its Verifi™ line of fingerprint biometric readers will secure ... and Mental Hygiene , ... (PRWEB) May 8, 2010 -- Zvetco Biometrics , a leader in fingerprint ...
... private insurance pays greater share today , MONDAY, May 10 ... States almost doubled between 1987 and 2005, with private insurers taking ... , Researchers led by Florence Tangka, a health economist at ... 1987 to that from 2001 to 2005. In 1987, the total ...
... ... is now available at SleepHappens.com. , ... (PRWEB) May 10, 2010 -- Mattress Warehouse is proud to announce ... Collection is exclusive to Mattress Warehouse and features unique BeautyStyle aesthetics and BeautyFeel support ...
Cached Medicine News:Health News:$1.9 million grant to help UCF find multiple sclerosis 'nerve-ana' 2Health News:Smarter use of existing treatment helps dramatically boost survival of young AML patients 2Health News:Differences in language circuits in the brain linked to dyslexia 2Health News:Zvetco Biometrics Delivers Needed Authentication for New York City Department of Health and Mental Hygiene 2Health News:Zvetco Biometrics Delivers Needed Authentication for New York City Department of Health and Mental Hygiene 3Health News:Mattress Warehouse Announces Its New Simmons Mattress Lineup 2
... Used for catheter positioning and exchange in ... the wire guide coils allows utilization of ... smooth transition to a very flexible tip. ... is the most rigid coiled wire guide ...
Supplied sterile in peel-open packages. Intended for one-time use....
... Used as an initial access wire into ... prior to an endourology procedure. The mandril type ... that of a .035 inch (0.89 mm) diameter ... guide is of spring coil construction over the ...
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: